Newsletter | 01 February 2003 Access News 8, Focus on Access Three Years On, February 2003 HIV/AIDS RESEARCH AND DEVELOPMENT TROPICAL & NEGLECTED DISEASES VACCINES The Access Campaign three years on is addressed in this issue of AccessNews, as well as the fear of another meningitis epidemic, Roche's failing of HIV patients, fighting against neglected diseases, no agreements at Doha and HIV positive children. Read, watch, share Filter by - Any -BlogEventsFeature storyInfographicInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefTopic overviewVideo Video Video | 07 March 2014 HIV/AIDS Africa HIV. Proof that the project is working Statement | 21 February 2014 HIV/AIDS MSF response to the licensing deal announced between Merck Sharp & Dohme and Cipla for the HIV medicine raltegravir 3 min Press release Press release | 10 December 2013 HIV/AIDS MSF calls for scale-up of ‘viral load’ monitoring to improve HIV treatment outcomes in developing countries 4 min Issue brief | 06 December 2013 HIV/AIDS HIV status? Undetectable Press release | 02 December 2013 HIV/AIDS Intellectual property and trade Tuberculosis Proposed shake-up to drug pricing framework risks middle-income countries paying more Video Video | 29 November 2013 HIV/AIDS HIV status: Undetectable Press release | 25 November 2013 HIV/AIDS Millions Still Waiting For AIDS Revolution Events | 19 November 2013 HIV/AIDS HIV Co-infections in India - When ARVs alone may not be enough Load More
Statement | 21 February 2014 HIV/AIDS MSF response to the licensing deal announced between Merck Sharp & Dohme and Cipla for the HIV medicine raltegravir 3 min
Press release Press release | 10 December 2013 HIV/AIDS MSF calls for scale-up of ‘viral load’ monitoring to improve HIV treatment outcomes in developing countries 4 min
Press release | 02 December 2013 HIV/AIDS Intellectual property and trade Tuberculosis Proposed shake-up to drug pricing framework risks middle-income countries paying more
